Physician profile
Mark C Rafalko
NPI 1578545059
$1,876.07
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.58 · 2020: $461 · 2021: $888 · 2022: $352 · 2023: $132 · 2024: $13.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $145.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $849.72 | 2020-2021 | |
| Boston Scientific Corporation | $199.35 | 2021-2022 | |
| Pacira Pharmaceuticals Incorporated | $140.93 | 2021-2023 | Exparel, Iovera, Zilretta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.76 | 2020-2022 | |
| Amgen INC. | $114.26 | 2020-2022 | |
| Lilly USA, LLC | $65.26 | 2023 | Emgality, Reyvow |
| Tersera Therapeutics LLC | $45.95 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $42.16 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $40.06 | 2023-2024 | Austedo Xr, Austedo |
| Grt US Holding, INC. | $37.53 | 2021 | |
| Vertos Medical, INC. | $35.10 | 2021 | |
| Almatica Pharma LLC | $25.83 | 2022 | |
| Rigel Pharmaceuticals, INC. | $24.30 | 2023 | Tavalisse, Rezlidhia |
| Supernus Pharmaceuticals, INC. | $22.95 | 2022 | |
| Medtronic, INC. | $18.38 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hospira, INC. | $17.49 | 2019 | |
| Bioventus LLC | $17.44 | 2022 | |
| Redhill Biopharma INC. | $16.35 | 2020 | |
| Scilex Pharmaceuticals INC. | $12.16 | 2022 | |
| Kaleo, INC. | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Rafalko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.